# Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

> **NCT00654186** · PHASE2 · COMPLETED · sponsor: **Oncology Specialists, S.C.** · enrollment: 32 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT00654186
- **Lead sponsor:** Oncology Specialists, S.C.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654186, "Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00654186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*